Drug Trial Radar · NCT06625320
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
500
Actual
Start
Oct 16, 2024
Primary completion
Jun 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Revolution Medicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Conditions
- Pancreatic Cancer
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
RMC-6236Drug
Oral Tablets
GemcitabineDrug
intravenous (IV) infusion
nab-paclitaxelDrug
IV infusion
IrinotecanDrug
IV infusion
Liposomal irinotecanDrug
IV infusion
5-fluorouracilDrug
IV infusion
leucovorinDrug
IV infusion
OxaliplatinDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) in the RAS G12-mutant populationTime frame: Up to approximately 3 years
- Overall survival (OS) in the RAS G12-mutant populationTime frame: Up to approximately 3 years
Locations
60 sites in 7 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Mayo Clinic Cancer Center - Phoenix
Phoenix, Arizona
City of Hope-Duarte
Duarte, California
Cedars-Sinai Medical Center
Los Angeles, California
UCLA
Los Angeles, California
UC San Diego Health Moores Cancer Center
San Diego, California
Mission Hall UCSF
San Francisco, California
Rocky Mountain Cancer
Aurora, Colorado
Mayo Clinic Cancer Center - Florida
Jacksonville, Florida
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Cancer Care Centers of Brevard Inc
Palm Bay, Florida
Moffitt Cancer Center
Tampa, Florida
The Queen's Medical Center
Honolulu, Hawaii
The University of Chicago Medical Center
Chicago, Illinois
Johns Hopkins
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Mayo Clinic Cancer Center - Rochester
Rochester, Minnesota
Washington University
St Louis, Missouri
Roswell Park Cancer Institute
Buffalo, New York
NYU Lagone Health
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Columbia University Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
Stephenson Cancer Center
Oklahoma City, Oklahoma
Oregon Health and Science University
Portland, Oregon
Abramson Cancer Center Clinical Research Unit
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Sarah Cannon Research Institute (Tennessee)
Nashville, Tennessee
Texas Oncology Sammons
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Texas Oncology - Central South
Irving, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Cancer Specialists
Fairfax, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Institut Paoli Calmettes
Marseille, France
Centre Eugene Marquis
Rennes, France
Hopital Paul Brousse
Villejuif, France
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.